Tech Company Financing Transactions
BioTheryX Funding Round
MSD Capital and private investors invested in a $35 million Series D venture round for BioTheryX. The round was announced on 7/29/2020.
Transaction Overview
Company Name
Announced On
7/29/2020
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series D
Investors
MSD Capital (Lead Investor) (Robert Platek)
Proceeds Purpose
this funding will support our ongoing work in protein modulation and degradation utilizing proprietary Protein Homeostatic Modulators (PHMs) and PHMÂ-based PROTACs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7966 Arjons Dr. D
San Diego, CA 92126
USA
San Diego, CA 92126
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, including protein degradation as well as multi-kinase inhibition, to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Stirling
Chief Scientific Officer
Frank Mercurio
Chief Technical Officer
Kyle Chan
President
Lawrence Zaslow
Browse more venture capital transactions:
Prev: 7/29/2020: Explorium venture capital transaction
Next: 7/29/2020: Wingocard venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs